Genotype‐guided antiplatelet treatment versus conventional therapy: A systematic review and meta‐analysis

Review of 16 studies (n=10,561, 8 studies were RCTs) found lower rates of major adverse cardiovascular events (RR 0.56, 95%CI 0.44‐0.73), stent thrombosis (0.40, 0.24‐0.67) and myocardial infarction (0.45, 0.35‐0.58) with genotype‐guided vs conventional treatment.

SPS commentary:

Authors note well‐organized RCTs and clinical trials are required to verify the benefit of genotype‐guided therapy.

British Journal of Clinical Pharmacology